Skip to content

Program / AmoyDx

AmoyDx molecular diagnostics for precision medicine in oncology

Amoy Diagnostics Co., Ltd. — AmoyDx — focuses on molecular diagnostics for precision medicine in oncology. As the representative for Serbia and Montenegro, Sineks Medical connects healthcare institutions with AmoyDx solutions for mutation detection, gene expression and the companion diagnostics approach.

Molecular diagnostics Precision oncology ADx-ARMS IVD / CE tests
AmoyDx molecular diagnostics
AmoyDx
Sineks Medical
Advanced medical technologies

About the program

AmoyDx develops tests for personalized oncology therapy

The company has a portfolio of molecular diagnostic tests focused on mutation detection and gene expression measurement in tumor tissue.

AmoyDx is a company focused on molecular diagnostics in precision medicine, especially in oncology. Its tests are used for biomarker analysis that may be important for therapy selection, indication monitoring and clinical decision-making.

The previous Sineks content highlights ADx-ARMS and Super-ARMS technologies, as well as a test portfolio that includes EGFR, RAS, ALK, BRAF, PIK3CA, ROS1 and other markers. The tests are intended for laboratories, healthcare institutions, academic institutions and pharmaceutical companies.

  • Molecular diagnostics for precision medicine in oncology.
  • Tests for mutation detection and gene expression measurement.
  • The portfolio includes biomarkers such as EGFR, RAS, ALK, BRAF, PIK3CA and ROS1.
  • Sineks Medical represents AmoyDx for Serbia and Montenegro.

Fields of application

Where do AmoyDx tests most often fit?

AmoyDx solutions are relevant for institutions and laboratories working with oncology samples, biomarkers and a personalized therapeutic approach.

Precision oncology

For clinical processes in which the therapeutic decision is connected with the molecular profile of the tumor and relevant biomarkers.

Molecular laboratories

For laboratories working with PCR, mutation analysis, FFPE sample processing and validated IVD tests.

Oncology institutions

For institutions that want to connect diagnostics, therapy selection and multidisciplinary decision-making in oncology.

Companion diagnostics

The AmoyDx portfolio can be connected with therapeutic indications and partnerships with pharmaceutical companies.

Academic institutions

For research and academic teams working with molecular markers and oncology samples.

Pharmaceutical companies

For cooperation in the development, validation and support of diagnostic solutions within personalized medicine.

Biomarkers and tests

Portfolio for key oncology markers

The AmoyDx portfolio includes multiple tests for mutations and genetic changes that are important in modern oncology diagnostics.

EGFR

Tests for biomarkers often considered in the context of lung cancer and targeted therapy.

KRAS / NRAS

Tests for detecting KRAS and NRAS mutations relevant for molecular diagnostics and therapeutic decision-making according to applicable protocols.

ALK / ROS1

Tests connected with precision oncology and the companion diagnostics approach.

BRAF / PIK3CA

Markers that may be part of a molecular profile and a wider diagnostic algorithm.

RET

Part of a wider portfolio of tests and panels for molecular oncology diagnostics.

FFPE samples

Previous content mentions tests focused on mutation detection and gene expression in FFPE tumor tissue.

Real-time PCR

The tests are based on proprietary real-time PCR technology called ADx-ARMS.

IVD application

Some tests have CE marking for diagnostic use in Europe, according to the previous content.

Technology

ADx-ARMS and Super-ARMS as the foundation of the AmoyDx approach

Previous Sineks content specifically highlights AmoyDx proprietary technologies for real-time PCR diagnostics and high testing sensitivity.

ADx-ARMS

Proprietary real-time PCR technology used in AmoyDx tests for mutation detection.

Super-ARMS

A technology platform connected with a more advanced approach to mutation detection in oncology samples.

Sensitivity and accuracy

Previous content states 1% sensitivity and 99% accuracy for AmoyDx tests, in the context of their validated systems.

Results in about 90 minutes

The tests are described as easy to perform, with results within about 90 minutes on common PCR instruments.

Process and users

Who are AmoyDx solutions intended for?

For AmoyDx, we do not display a generic customer portfolio. It is more important to show user types and the discussion process around laboratory needs.

FAQ

Frequently asked questions about AmoyDx solutions

Answers for laboratories, healthcare institutions and teams considering AmoyDx molecular diagnostics.

AmoyDx is a company focused on molecular diagnostics for precision medicine in oncology, including tests for mutations, gene expression and biomarkers relevant for therapeutic decision-making.

Previous Sineks content lists EGFR, RAS, ALK, BRAF, PIK3CA, ROS1, RET and related panels for molecular oncology diagnostics.

They are intended for molecular laboratories, healthcare institutions, oncology centers, academic institutions and pharmaceutical companies, in accordance with indications and laboratory conditions.

Send a description of the laboratory, types of tests you are interested in, existing PCR equipment and clinical indications. Based on that, Sineks Medical can help choose the appropriate solution.

Back To Top